Bendamustine
Educational summary, not a formulary. Dosing is quoted from the Makindo chapters and topics site. The other sections are draft summaries not yet checked line by line against the BNF or SPC. Check dose, indication, interactions and monitoring in the BNF entry for Bendamustine and local guidelines before prescribing.
Alkylating cytotoxic
Mechanism
Alkylating agent with antimetabolite properties.
Uses
CLL, indolent lymphoma, myeloma.
Dosing
No dose is given in the chapters. See the BNF.
Side effects
Myelosuppression, infusion reactions, skin reactions, infections.
Interactions
Allopurinol increases skin reaction risk.
Contraindications and cautions
Severe liver impairment
Monitoring
FBC, LFT
Pregnancy and breastfeeding
Contraindicated
Renal and hepatic impairment
Avoid in moderate to severe hepatic or renal impairment
Overdose and reversal
Supportive
Special advice
Infection prophylaxis; check FBC before each cycle.
More from the textbook: uses, cautions and other points
- Purine analogues (fludarabine, cladribine) and bendamustine - profound immunosuppression - irradiated blood for life , PCP prophylaxis.
Haematology: Anatomy Physiology and Pharmacology - Treat only when symptomatic: BTK inhibitors (zanubrutinib, ibrutinib) or bendamustine-rituximab; plasmapheresis for hyperviscosity. Rituximab can cause an IgM "flare", so use with caution when IgM is very high.
Haematology: Myeloma and Lymphoma - PJP prophylaxis (co-trimoxazole) with high-dose steroids, bendamustine and purine analogues; aciclovir for herpes viruses; antifungals in prolonged neutropenia.
Haematology: Myeloma and Lymphoma - Bendamustine | Indolent lymphoma, mantle cell, Waldenström; prolonged lymphopenia and opportunistic infection (PJP prophylaxis), skin rashes.
Haematology: Myeloma and Lymphoma - Irradiated components (to prevent transfusion-associated GvHD) - after purine analogues (fludarabine, cladribine, bendamustine), Hodgkin's lymphoma , stem cell transplant, some congenital immunodeficiencies, intrauterine transfusion, HLA-matched or family-donated components, CAR-T therapy.
Haematology: Anatomy Physiology and Pharmacology - Irradiated blood if treated with purine analogues or bendamustine.
Haematology: Leukaemias, myeloproliferative neoplasms and myelodysplasia - Treatment with purine analogues (fludarabine, cladribine), bendamustine, alemtuzumab, ATG.
Haematology: Haemoglobinopathies and Transfusion - Treat when there are symptoms, bulky disease, cytopenias, organ compromise or rapid progression: an anti-CD20 antibody (rituximab or obinutuzumab) with chemotherapy (bendamustine, CVP or CHOP), then anti-CD20 maintenance.
Haematology: Myeloma and Lymphoma
Where it is discussed in the book
- Haematology: Anatomy Physiology and Pharmacology (2 mentions)
- Haematology: Leukaemias, myeloproliferative neoplasms and myelodysplasia (1 mention)
- Haematology: Haemoglobinopathies and Transfusion (1 mention)
- Haematology: Myeloma and Lymphoma (5 mentions)
- Clinical Immunology: Biologics, immunotherapy, checkpoint toxicity and transplant immunology (1 mention)